KLRB1 and hepatocellular carcinoma: In conclusion, this study conducted a comprehensive assessment of CD161, indicating its correlation with a favorable prognosis and immune infiltration in hepatocellular carcinoma, exploring its regulatory role in the immune microenvironment, and highlighting its potential as a prospective biomarker for immunotherapy.